•
Apr 30, 2022

Cooper Q2 2022 Earnings Report

Reported a revenue increase of 15% year-over-year, with strong growth in both CooperVision and CooperSurgical segments.

Key Takeaways

CooperCompanies announced strong second quarter results with revenue up 15% year-over-year to $829.8 million. Both CooperVision and CooperSurgical showed strong revenue growth. GAAP diluted earnings per share increased to $2.55, while non-GAAP diluted earnings per share decreased to $3.24.

Revenue increased 15% year-over-year to $829.8 million.

CooperVision revenue was up 6% to $553.8 million.

CooperSurgical revenue was up 40% to $276.0 million.

GAAP diluted earnings per share increased to $2.55, up from $2.36 last year.

Total Revenue
$830M
Previous year: $720M
+15.3%
EPS
$0.81
Previous year: $0.85
-4.7%
Gross margin
64%
Previous year: 68%
-5.9%
Operating margin
16%
Previous year: 20%
-20.0%
Gross Profit
$533M
Previous year: $487M
+9.3%
Cash and Equivalents
$399M
Previous year: $106M
+277.0%
Free Cash Flow
$88.4M
Previous year: $143M
-38.1%
Total Assets
$11.8B
Previous year: $9.01B
+30.7%

Cooper

Cooper

Cooper Revenue by Segment

Cooper Revenue by Geographic Location

Forward Guidance

The Company updated its fiscal year 2022 financial guidance.

Positive Outlook

  • Fiscal 2022 total revenue $3,280 - $3,312 million (organic growth of 9% to 10%)
  • CVI revenue $2,225 - $2,247 million (organic growth of 10% to 11%)
  • CSI revenue $1,055 - $1,065 million (organic growth of 6% to 7%)
  • Fiscal 2022 non-GAAP diluted EPS $13.09 - $13.29
  • Assumes a 50 basis point rate increase in both June and July and a 25 basis point rate increase in September

Revenue & Expenses

Visualization of income flow from segment revenue to net income